Reply: The Value of 18F-FDG PET/CT in the Assessment of Cardiac Malignancy Remains to Be Defined
K Rahbar, O Schober, M Weckesser - Journal of Nuclear Medicine, 2012 - Soc Nuclear Med
TO THE EDITOR: We read with great interest the recent article by Rahbar et al. titled
“Differentiation of Malignant and Benign Cardiac Tumors Using 18F-FDG PET/CT”(1). The …
“Differentiation of Malignant and Benign Cardiac Tumors Using 18F-FDG PET/CT”(1). The …
PET prediction of response to trastuzumab in ErbB2-positive human xenograft model
E Tagliabue, M Campiglio, A Balsari… - Journal of Nuclear …, 2012 - Soc Nuclear Med
TO THE EDITOR: Recently, Kramer-Marek et al.(1) published a very interesting study about
the use of Affibody-based PET to monitor response to trastuzumab in a human xenograft …
the use of Affibody-based PET to monitor response to trastuzumab in a human xenograft …